A Multicenter, Randomized, Double-blind, Placebo-controlled, Crossover Trial to Evaluate the Effects of Evolocumab Added to Standard Lipid-lowering Therapy on Fasting and Post Fat Load Lipids in Patients With Familial Dysbetalipoproteinemia
Latest Information Update: 07 Oct 2022
Price :
$35 *
At a glance
- Drugs Evolocumab (Primary)
- Indications Hyperlipoproteinaemia type III
- Focus Pharmacokinetics
- Acronyms EVOLVE-FD
- 29 Aug 2022 Primary endpoint has been met (AUC (area under the curve) non-HDL-cholesterol) , according Results presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology
- 29 Aug 2022 Status changed to completed , according to Results presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology
- 29 Aug 2022 Results presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology